| Not Yet Recruiting | A Study of APG-3288 in Relapsed/Refractory Blood Cancers Relapsed/Refractory Hematological Malignancies, Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia (CLL/SLL, Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL; Including Richter Transformation) | Phase 1 | 2026-03-01 |
| Recruiting | Pharmacokinetics of Olverembatinib in Participants With Hepatic Impairment Pharmacokinetic, Olverembatinib | Phase 1 | 2025-11-11 |
| Recruiting | Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysp Higher-risk Myelodysplastic Syndrome | Phase 3 | 2025-01-22 |
| Recruiting | APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced S Platinum-resistant Recurrent Ovarian Cancer, Advanced Solid Tumor | Phase 1 | 2024-12-17 |
| Recruiting | A Study of Olverembatinib in SDH-deficient GIST. GIST | Phase 3 | 2024-11-11 |
| Recruiting | A Study of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus. SLE | Phase 1 / Phase 2 | 2024-08-09 |
| Recruiting | A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia Acute Myeloid Leukemia | Phase 3 | 2024-06-11 |
| Recruiting | A Global Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagn CLL/SLL | Phase 3 | 2024-04-07 |
| Recruiting | Study of Olverembatinib (HQP1351) in Patients With CP-CML Chronic Myeloid Leukemia, CML, CML, Chronic Phase | Phase 3 | 2024-02-05 |
| Recruiting | Global Trial in APG2575 for Patients With CLL/SLL CLL/SLL | Phase 3 | 2023-12-20 |
| Recruiting | A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ALL. Ph+ ALL | Phase 3 | 2023-08-31 |
| Recruiting | A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of APG-5918. Anemia | Phase 1 | 2023-03-13 |
| Recruiting | APG-115 Alone or in Combination With APG-2575 in Children With Recurrent or Refractory Neuroblastoma or Solid Neuroblastoma, Solid Tumor | Phase 1 | 2023-02-28 |
| Unknown | Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas Nasopharyngeal Carcinoma, Castrate Resistant Prostate Cancer, Gastric Cancer | Phase 1 | 2022-09-30 |
| Completed | The Absorption, Metabolism and Excretion of [14C]APG-2575 in Healthy Subjects Pharmacokinetics | Phase 1 | 2022-09-14 |
| Unknown | APG-1252 Monotherapy or in Combination With Other Therapeutic Agent in Subjects With Relapsed or Refractory No NHL, Adult | Phase 1 / Phase 2 | 2022-06-14 |
| Terminated | A Study of Pelcitoclax (APG-1252) in Patients With Neuroendocrine Tumors Neuroendocrine Tumors | Phase 1 | 2022-01-06 |
| Recruiting | Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | 2021-12-28 |
| Unknown | APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myelo Multiple Myeloma, Amyloidosis | Phase 1 / Phase 2 | 2021-12-23 |
| Suspended | A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Ca Breast Cancer, Solid Tumor, Adult | Phase 1 / Phase 2 | 2021-08-13 |
| Unknown | A Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML) AML, Adult | Phase 1 / Phase 2 | 2021-07-30 |
| Recruiting | A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NH T-Prolymphocytic Leukemia, Non-Hodgkins Lymphoma | Phase 2 | 2021-07-12 |
| Completed | APG-2575 Single Agent or in Combination With Ibrutinib or Rituximab in Patients With Waldenström Macroglobulin Waldenstrom Macroglobulinemia | Phase 1 | 2021-05-30 |
| Recruiting | APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors Liposarcoma, Advanced Solid Tumor | Phase 1 / Phase 2 | 2021-05-26 |
| Unknown | APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple Multiple Myeloma | Phase 1 / Phase 2 | 2021-04-13 |
| Terminated | APG-1387 Plus Chemotherapy in Advanced Pancreatic Adenocarcinoma Advanced Pancreatic Cancer | Phase 1 / Phase 2 | 2021-03-17 |
| Withdrawn | A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy Myelofibrosis | Phase 1 / Phase 2 | 2020-12-15 |
| Unknown | A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS AML, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia | Phase 1 / Phase 2 | 2020-12-04 |
| Recruiting | Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML Relapsed/Refractory Acute Myeloid Leukaemia, Myeloid Malignancy | Phase 1 / Phase 2 | 2020-09-28 |
| Recruiting | Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 1 / Phase 2 | 2020-08-31 |
| Terminated | Study of APG-1252 Plus Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung Cancer Small Cell Lung Cancer | Phase 1 / Phase 2 | 2020-08-20 |
| Recruiting | A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) | Phase 1 | 2020-07-06 |
| Unknown | A Clinical Study of APG-1387 in Combination With Entecavir in Patients With Chronic Hepatitis B Hepatitis B, Chronic Hep B, HBV | Phase 2 | 2020-06-03 |
| Terminated | Dose-escalation Study of APG-1387 and Toripalimab in Solid Tumors Advanced Solid Tumor | Phase 1 / Phase 2 | 2020-04-10 |
| Recruiting | Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL CLL/SLL | Phase 1 | 2020-03-02 |
| Recruiting | Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL Leukemia, Myeloid, Chronic, Myeloid Leukemia, Chronic Myeloid Leukemia | Phase 1 | 2020-01-09 |
| Completed | The Absorption, Metabolism and Excretion of [14C] HQP1351 in Humans Chronic Myeloid Leukemia (CML) | Phase 1 | 2019-11-19 |
| Completed | A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase Chronic Myeloid Leukemia, Chronic Phase | Phase 2 | 2019-10-21 |
| Active Not Recruiting | A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients EGFR Positive Non-small Cell Lung Cancer | Phase 1 | 2019-07-04 |
| Active Not Recruiting | A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignancies Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma | Phase 1 | 2019-06-03 |
| Recruiting | APG-2449 in Patients With Advanced Solid Tumors Advanced Solid Cancer, Non Small Cell Lung Cancer, Esophageal Cancer | Phase 1 | 2019-05-27 |
| Unknown | A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Accelerated Phase With T315I Mutation Chronic Myeloid Leukemia - Accelerated Phase | Phase 2 | 2019-04-08 |
| Unknown | A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Chronic Phase With T315I Mutation Chronic Myeloid Leukemia, Chronic Phase | Phase 2 | 2019-04-08 |
| Completed | Pharmacokinetics Profiles of HQP1351 Under Fasting and High-fat Meals in Patients With Chronic Myeloid Leukemi Chronic Myeloid Leukemia, Chronic Phase | Phase 1 | 2019-03-25 |
| Active Not Recruiting | A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas Unresectable or Metastatic Melanoma or Advanced Solid Tumors, Melanoma, Uveal Melanoma | Phase 1 / Phase 2 | 2018-08-29 |
| Recruiting | APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies Hematologic Malignancies | EARLY_Phase 1 | 2018-08-07 |
| Recruiting | A Study of HQP1351 in Patients With GIST or Other Solid Tumors Gastrointestinal Stromal Tumor (GIST), Solid Tumor, Adult | Phase 1 | 2018-07-11 |
| Completed | APG-1387 Study of Safety, Tolerability ,PK/PD in Patients With Chronic Hepatitis B Chronic Hepatitis B | Phase 1 | 2018-07-04 |
| Terminated | APG-1252 in Patients With SCLC or Advanced Solid Tumors Small Cell Lung Cancer and Other Solid Tumors | Phase 1 | 2017-12-01 |
| Completed | APG-1387 in Patients With Advanced Solid Tumors or Hematologic Malignancies Advanced Solid Tumors or Hematologic Malignancies | Phase 1 | 2017-11-21 |
| Completed | A Study of APG-1252 in Patients With SCLC or Other Solid Tumors Small Cell Lung Cancer, Solid Tumor | Phase 1 | 2017-02-12 |
| Completed | APG-115 in Patients With Advanced Solid Tumors or Lymphomas Patients With Advanced Solid Tumor or Lymphoma | Phase 1 | 2016-10-01 |
| Available | Named Patient Program for Olverembatinib (HQP1351) | — | — |